November 04, 2020 SITC 2020 – second chances for Merck & Co and Oncosec Among late-breaking abstracts whose titles have just gone live two mechanisms have a chance to redeem themselves.
November 04, 2019 SITC 2019 preview – Pieris joins the quest for a better Herceptin Any signs of efficacy with PRS-343 could help Pieris claw back some of its recent losses, but Her2 targeting is increasingly competitive.
October 27, 2019 Triple meeting – targeted focus validates Merus’s change of tack Merus’s anti-Her2/Her3 bispecific could have a future in a new targeted setting.
August 31, 2017 Corporate venture firms – dedicated followers of fashion? Eagerly pursuing all the latest fads and trends.